Free Trial

ACADIA Pharmaceuticals (ACAD) News Today

→ You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad)
Free ACAD Stock Alerts
$14.89
-0.41 (-2.68%)
(As of 06/7/2024 08:51 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 8 at 4:28 PM | marketbeat.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Sectoral Asset Management Inc.
Sectoral Asset Management Inc. cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 92.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,060 shares of the biopharmaceutical comp
June 7 at 11:15 PM | marketbeat.com
RTW Investments LP Has $352.35 Million Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
RTW Investments LP reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,253,551 shares of the biopharmaceut
June 5, 2024 | seekingalpha.com
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
June 4, 2024 | marketbeat.com
Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company's stock
June 4, 2024 | americanbankingnews.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q1 2026 Earnings of $0.22 Per Share
June 3, 2024 | marketbeat.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Purchased by Finepoint Capital LP
Finepoint Capital LP raised its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 38.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 769,653 shares of the biopharmaceutical company's stoc
June 3, 2024 | marketbeat.com
Q1 2026 EPS Estimates for ACADIA Pharmaceuticals Inc. Reduced by Analyst (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Zacks Research reduced their Q1 2026 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 29th. Zacks Research analyst A. Chakraborty now expects that th
May 31, 2024 | americanbankingnews.com
Q2 2024 Earnings Estimate for ACADIA Pharmaceuticals Inc. Issued By Zacks Research (NASDAQ:ACAD)
May 30, 2024 | marketbeat.com
1,443,218 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Norges Bank
Norges Bank bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,443,218 shares of the biopharmaceutical com
May 29, 2024 | marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 52-Week Low at $14.60
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 12-Month Low at $14.60
May 27, 2024 | finanznachrichten.de
Neuren Pharmaceuticals Ltd: Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
May 23, 2024 | markets.businessinsider.com
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
May 22, 2024 | marketbeat.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and twelve have issued a
May 21, 2024 | marketbeat.com
Massachusetts Financial Services Co. MA Acquires New Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Massachusetts Financial Services Co. MA bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 60,564 shares of
May 20, 2024 | marketbeat.com
Bridger Management LLC Invests $3.67 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Bridger Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 117,341 shares of the biopharmaceutical company's stock, valued at a
May 19, 2024 | marketbeat.com
BNP Paribas Financial Markets Decreases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
BNP Paribas Financial Markets lowered its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 24.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 229,765 shares of the biopharmaceutical company's stock after selling 75,403 sha
May 17, 2024 | businesswire.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Elicio Therapeutics (ELTX)
May 15, 2024 | stocknews.com
3 Pharma Stocks to Buy for Potential Financial Fortunes
May 15, 2024 | marketbeat.com
M&G Investment Management Ltd. Acquires New Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
M&G Investment Management Ltd. bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 333,824 shares of the biopharmaceutical company
May 15, 2024 | businesswire.com
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 12, 2024 | marketbeat.com
Jump Financial LLC Purchases 89,053 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Jump Financial LLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 326.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 116,341 shares of the biophar
May 11, 2024 | markets.businessinsider.com
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
May 11, 2024 | finance.yahoo.com
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10, 2024 | markets.businessinsider.com
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
May 10, 2024 | finance.yahoo.com
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 10, 2024 | marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $22.00 by Analysts at Bank of America
Bank of America decreased their price objective on shares of ACADIA Pharmaceuticals from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Friday.
May 10, 2024 | marketbeat.com
Brokers Set Expectations for ACADIA Pharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Stock analysts at Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceu
May 9, 2024 | marketbeat.com
Citigroup Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00
Citigroup decreased their price objective on shares of ACADIA Pharmaceuticals from $30.19 to $30.00 and set a "buy" rating for the company in a research report on Thursday.
May 9, 2024 | markets.businessinsider.com
Positive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term Opportunities
May 9, 2024 | markets.businessinsider.com
Maintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth Prospects
May 9, 2024 | msn.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
May 9, 2024 | businesswire.com
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 9, 2024 | marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.06. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $205.83 million during the quarter, compared to the consensus estimate of $208.31 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The firm's quarterly revenue was up 73.8% compared to the same quarter last year.
May 9, 2024 | marketbeat.com
ACADIA Pharmaceuticals' (ACAD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday.
May 9, 2024 | marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 12-Month Low Following Analyst Downgrade
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low Following Analyst Downgrade
May 9, 2024 | markets.businessinsider.com
ACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy Rating
May 9, 2024 | finance.yahoo.com
ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...
May 8, 2024 | investorplace.com
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 8, 2024 | seekingalpha.com
ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation
May 8, 2024 | marketbeat.com
143,054 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Fisher Asset Management LLC
Fisher Asset Management LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,054 sh
May 7, 2024 | markets.businessinsider.com
ACADIA Pharmaceuticals is about to announce its earnings — here's what Wall Street expects
May 6, 2024 | marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Market Perform Rating at Oppenheimer
Oppenheimer reissued a "market perform" rating and set a $19.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday.
May 5, 2024 | insidertrades.com
James Kihara Sells 1,326 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
May 5, 2024 | insidertrades.com
Brendan Teehan Sells 3,477 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
May 4, 2024 | finance.yahoo.com
Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
May 2, 2024 | stocknews.com
Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now
May 2, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Sarepta Therapeutics (SRPT) and Acadia Healthcare (ACHC)
May 1, 2024 | finance.yahoo.com
Newron’s add-on schizophrenia therapy finds success in Phase II/III trial
May 1, 2024 | marketbeat.com
ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday
ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589710)
Get ACADIA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Top 5 Tech Stocks to Buy for 2024 (Ad)

The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…

Click below for your free report "Top 5 Tech Stocks to Buy in 2024",

ACAD Media Mentions By Week

ACAD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACAD
News Sentiment
▼
0.46

0.76
▲
Average
Medical
News Sentiment

ACAD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACAD Articles
This Week
▼
8

6
▲
ACAD Articles
Average Week

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ACAD) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
You won't believe what Citigroup just did to it's depositors
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...
American Alternative | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
RSVP: Charles Payne’s Cash Flow Workshop
Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...
Unstoppable Prosperity | Sponsored